Source disclosure: February 12, 2026
Mitsubishi Chemical Group Corporation [4188.T]
TOKYO, February 12, 2026 — Mitsubishi Chemical Group Corporation, represented by President and CEO Mr. Manabu Tsukamoto (Code Number: 4188, Tokyo Prime Market), has completed an interim review of its consolidated quarterly financial statements for the third quarter ending December 31, 2025, as per the International Financial Reporting Standards (IFRS). The company disclosed these figures on February 5, 2026, and now confirms that there have been no changes to the previously announced summary.
The corporation reported its consolidated earnings for the first nine months of the fiscal year ending March 2026, showing mixed results compared to the same period last year. Sales revenue decreased by 8.2% to ¥2,737,283 million from ¥2,982,711 million in the corresponding period of the previous fiscal year. Core operating income also declined slightly by 2.4%, amounting to ¥185,622 million against ¥190,228 million in the prior-year period. However, net income attributable to owners of the parent increased significantly by 77.6% to ¥105,429 million from ¥59,369 million in the comparable quarter of 2025.
In terms of profitability metrics, basic earnings per share improved substantially to ¥76.70 (¥76.67) in the current quarter compared to ¥41.72 (¥41.70) in the same quarter last year. Pre-tax profit for the third quarter of the fiscal year 2026 was recorded at ¥89,340 million, marking a decrease of 23.9%. This contrasts with a larger decline of 38.8% to ¥117,384 million during the equivalent period in the preceding fiscal year.
Regarding significant events impacting the financials, Mitsubishi Chemical transferred all shares and related assets of its subsidiary, Mitsubishi Tanabe Pharma Corporation, renamed to Tanabe Pharma Corporation since December 1, 2025, through absorption spin-off following approval at the regular shareholders' meeting held on June 25, 2025. Consequently, operations of this entity and its subsidiaries were excluded from continuing operations starting July 1, 2025. As such, the reported figures reflect only the ongoing business activities excluding non-recurring items associated with the divested pharmaceutical unit.
For dividend distribution, the company maintained its quarterly payout rate of ¥16.00 per share for the second quarter of the fiscal year 2026, aligning with the annualized forecast of ¥32.00 per share for the full fiscal year. No adjustments have been made to the latest dividend projections released by the firm.
Looking ahead, Mitsubishi Chemical forecasts a sales 0% from the previous fiscal year's total. Despite this reduction, core operating income is expected to rise by 9.2% to ¥250,000 million. Net income attributable to owners of the parent is anticipated to be ¥47,000 million, reflecting a modest increase of 4.4% over the previous year’s figure. These revised expectations indicate a more cautious outlook amid challenging market conditions.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing